Fosun Pharma (02696): The European Commission approved HLX14 (denosumab) for the treatment of osteoporosis in specific populations.

Intellimix Financial News APP, Fosun Pharma (02696) announced that recently, the marketing authorization applications (MAAs) for the products BILDYOS and BILPREVDA have been approved by the European Commission (EC). The trademarks of these products are registered in the EU by N.V. Organon. This approval means that BILDYOS and BILPREVDA have obtained centralized marketing authorization in all EU member states as well as Iceland, Liechtenstein, and Norway (each being a European Economic Area (EEA) country). The approved indications include all indications approved for Prolia and XGEVA in the EU, specifically: